 Connection
Peter Fecci to Animals
This is a "connection" page, showing publications Peter Fecci has written about Animals.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.897 |
|
|
|
-
Williams MM, Haskell-Mendoza AP, Massat EA, Mott BT, Smith EC, Zachem TJ, Loebel F, Cramer CK, Chan MD, Laxton AW, White JJ, Goodwin CR, Codd PJ, Fecci PE. Contemporary Management of Radiation Necrosis: Insights and Avenues. Clin Cancer Res. 2026 May 01; 32(9):1606-1614.
Score: 0.050
-
Hoyt-Miggelbrink AM, Waibl Polania J, Wachsmuth L, Lorrey S, Mohan A, Hardigan A, Blandford E, Lerner E, Wilkinson D, Hotchkiss KM, Cook S, Hemmers S, Patel A, Ayasoufi K, Fecci P. Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. Clin Cancer Res. 2026 Feb 17; 32(4):782-800.
Score: 0.049
-
Mariani CL, Wachsmuth LP, Bramall AN, Meritet DM, Hatfield J, Tsvankin V, Keenihan EK, Tokarz DA, Tyc R, Nolan MW, Fecci PE. Adapting Laser Interstitial Thermal Therapy for the Treatment of Naturally Occurring Intracranial Tumors in Dogs. Clin Cancer Res. 2025 Oct 15; 31(20):4372-4382.
Score: 0.048
-
Singh K, Hotchkiss KM, Cook SL, Noldner P, Zhou Y, Moelker EM, Railton CO, Blandford EE, Puviindran BJ, Wallace SE, Norberg PK, Archer GE, Shaz BH, Ayasoufi K, Sampson JH, Khasraw M, Fecci PE. IL-7-mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models. J Clin Invest. 2025 Jun 16; 135(12).
Score: 0.046
-
Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E, Woroniecka K, Finlay JB, Ayasoufi K, Fecci PE. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity. 2025 01 14; 58(1):232-246.e6.
Score: 0.045
-
Haskell-Mendoza AP, Srinivasan ES, Vo-Dinh T, Fecci PE. Leveraging gold nanostars for precision laser interstitial thermal therapy. Oncotarget. 2024 06 14; 15:389-391.
Score: 0.043
-
Srinivasan ES, Liu Y, Odion RA, Chongsathidkiet P, Wachsmuth LP, Haskell-Mendoza AP, Edwards RM, Canning AJ, Willoughby G, Hinton J, Norton SJ, Lascola CD, Maccarini PF, Mariani CL, Vo-Dinh T, Fecci PE. Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors. Clin Cancer Res. 2023 08 15; 29(16):3214-3224.
Score: 0.041
-
Lerner EC, Woroniecka KI, D'Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, Waibl-Polania J, Wachsmuth LP, Miggelbrink AM, Jackson JD, Cui X, Raj JA, Tomaszewski WH, Cook SL, Sampson JH, Patel AP, Khasraw M, Gunn MD, Fecci PE. CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer. 2023 09; 4(9):1258-1272.
Score: 0.041
-
Waibl Polania J, Lerner EC, Wilkinson DS, Hoyt-Miggelbrink A, Fecci PE. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. Front Immunol. 2021; 12:777073.
Score: 0.036
-
Miggelbrink AM, Jackson JD, Lorrey SJ, Srinivasan ES, Waibl-Polania J, Wilkinson DS, Fecci PE. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? Clin Cancer Res. 2021 11 01; 27(21):5742-5752.
Score: 0.035
-
Woroniecka KI, Rhodin KE, Dechant C, Cui X, Chongsathidkiet P, Wilkinson D, Waibl-Polania J, Sanchez-Perez L, Fecci PE. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. Clin Cancer Res. 2020 03 15; 26(6):1349-1358.
Score: 0.032
-
Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, Woroniecka KI, Cui X, Shen SH, Rhodin KE, Tsvankin V, Everitt J, Sanchez-Perez L, Healy P, McLendon RE, Codd PJ, Dunn IF, Fecci PE. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res. 2020 03 01; 26(5):1141-1151.
Score: 0.032
-
Lorrey SJ, Sanchez-Perez L, Fecci PE. Rescuing imperfect antigens for immuno-oncology. Nat Biotechnol. 2019 09; 37(9):1002-1003.
Score: 0.031
-
Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg. 2019 09 01; 131(3):657-666.
Score: 0.031
-
Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018 09; 24(9):1459-1468.
Score: 0.029
-
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018 09 01; 24(17):4175-4186.
Score: 0.028
-
Woroniecka K, Chongsathidkiet P, Elsamadicy A, Farber H, Cui X, Fecci PE. Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma. Methods Mol Biol. 2018; 1741:221-226.
Score: 0.028
-
Fecci PE, Babu R, Adamson DC, Sampson JH. Editorial: Turning fluorescence into black and white. J Neurosurg. 2015 Jun; 122(6):1356-8.
Score: 0.023
-
Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007 Apr 01; 13(7):2158-67.
Score: 0.013
-
Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4294-305.
Score: 0.013
-
Shen S, Mohan AA, Hotchkiss KM, Cook S, Patel K, Moelker E, Puviindran B, Gonzalez AT, Zaidi S, Spellicy S, Schwartz A, Suryadevara C, Wilkinson D, Ayasoufi K, Fecci PE, Sanchez-Perez L, Sampson J, Patel A. IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma. J Immunother Cancer. 2026 Mar 24; 14(3).
Score: 0.012
-
Graham-Gurysh EG, Woodring RN, Simpson SR, Mendell SE, Lukesh NR, Pena ES, Moore KM, Ontiveros-Padilla LA, Hendricksen AT, Lopez AM, Williamson GL, Murphy CT, Genito CJ, Hipp KA, Singh G, Zamboni WC, Hingtgen SD, Fecci PE, Bachelder EM, Ainslie KM. Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice. Nat Commun. 2025 Sep 29; 16(1):8603.
Score: 0.012
-
Whiteley AE, Ma D, Wang L, Yu SY, Yin C, Price TT, Simon BG, Xu KR, Marsh KA, Brockman ML, Prioleau TM, Zhou KI, Cui X, Fecci PE, Jeck WR, McCall CM, Neff JL, Sipkins DA. Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis. Science. 2024 06 21; 384(6702):eadh5548.
Score: 0.011
-
Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003 Aug-Sep; 64(1-2):161-76.
Score: 0.010
-
Fecci PE, Gromeier M, Sampson JH. Viruses in the treatment of brain tumors. Neuroimaging Clin N Am. 2002 Nov; 12(4):553-70.
Score: 0.010
-
Fecci PE, Sampson JH. Clinical immunotherapy for brain tumors. Neuroimaging Clin N Am. 2002 Nov; 12(4):641-64.
Score: 0.010
-
Tomaszewski WH, Waibl-Polania J, Miggelbrink AM, Chakraborty MA, Fecci PE, Sampson JH, Gunn MD. Broad immunophenotyping of the murine brain tumor microenvironment. J Immunol Methods. 2021 12; 499:113158.
Score: 0.009
-
Otvos B, Alban TJ, Grabowski MM, Bayik D, Mulkearns-Hubert EE, Radivoyevitch T, Rabljenovic A, Johnson S, Androjna C, Mohammadi AM, Barnett GH, Ahluwalia MS, Vogelbaum MA, Fecci PE, Lathia JD. Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. Clin Cancer Res. 2021 04 01; 27(7):2038-2049.
Score: 0.009
-
Huang MN, Nicholson LT, Batich KA, Swartz AM, Kopin D, Wellford S, Prabhakar VK, Woroniecka K, Nair SK, Fecci PE, Sampson JH, Gunn MD. Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. J Clin Invest. 2020 02 03; 130(2):774-788.
Score: 0.008
-
Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020 01; 20(1):12-25.
Score: 0.008
-
Liu Y, Chongsathidkiet P, Crawford BM, Odion R, Dechant CA, Kemeny HR, Cui X, Maccarini PF, Lascola CD, Fecci PE, Vo-Dinh T. Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory. Immunotherapy. 2019 10; 11(15):1293-1302.
Score: 0.008
-
Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L. Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clin Cancer Res. 2019 01 01; 25(1):358-368.
Score: 0.007
-
Atik AF, Suryadevara CM, Schweller RM, West JL, Healy P, Herndon Ii JE, Congdon KL, Sanchez-Perez L, McLendon RE, Archer GE, Fecci P, Sampson JH. Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. J Clin Neurosci. 2018 Oct; 56:163-168.
Score: 0.007
-
Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 06 11; 6(1):51.
Score: 0.007
-
Yoon SW, Tsvankin V, Shrock Z, Meng B, Zhang X, Dewhirst M, Fecci P, Adamson J, Oldham M. Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):794-801.
Score: 0.007
-
Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, Sampson JH. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opin Biol Ther. 2017 04; 17(4):507-513.
Score: 0.007
-
Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf. 2017 Mar; 16(3):277-287.
Score: 0.006
-
Oldham M, Yoon P, Fathi Z, Beyer WF, Adamson J, Liu L, Alcorta D, Xia W, Osada T, Liu C, Yang XY, Dodd RD, Herndon JE, Meng B, Kirsch DG, Lyerly HK, Dewhirst MW, Fecci P, Walder H, Spector NL. X-Ray Psoralen Activated Cancer Therapy (X-PACT). PLoS One. 2016; 11(9):e0162078.
Score: 0.006
-
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501.
Score: 0.006
-
Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 01; 76(5):999-1008.
Score: 0.006
-
Gedeon PC, Riccione KA, Fecci PE, Sampson JH. Antibody-based immunotherapy for malignant glioma. Semin Oncol. 2014 Aug; 41(4):496-510.
Score: 0.005
-
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec; 3(12):1355-63.
Score: 0.005
-
Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):12006-11.
Score: 0.005
-
Choi BD, Fecci PE, Sampson JH. Regulatory T cells move in when gliomas say "I Do". Clin Cancer Res. 2012 Nov 15; 18(22):6086-8.
Score: 0.005
-
Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery. 2012 Aug; 71(2):201-22; discussion 222-3.
Score: 0.005
-
Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012 Jun; 35(5):385-9.
Score: 0.005
-
Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008 Apr; 222:70-100.
Score: 0.004
-
Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurg Rev. 2008 Apr; 31(2):141-55; discussion 155.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|